BidaskClub upgraded shares of Agenus (NASDAQ:AGEN) from a sell rating to a hold rating in a report issued on Saturday morning.
A number of other analysts also recently weighed in on the stock. Zacks Investment Research raised shares of Agenus from a hold rating to a buy rating and set a $4.25 price target for the company in a research report on Wednesday, October 25th. ValuEngine downgraded shares of Agenus from a sell rating to a strong sell rating in a research report on Friday, December 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $5.81.
Shares of Agenus (NASDAQ AGEN) opened at $4.35 on Friday. Agenus has a 1 year low of $3.20 and a 1 year high of $5.45. The company has a debt-to-equity ratio of -2.39, a quick ratio of 1.55 and a current ratio of 1.55. The firm has a market cap of $435.80, a P/E ratio of -3.72 and a beta of 2.10.
Institutional investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC acquired a new position in Agenus in the fourth quarter worth $124,000. Raymond James & Associates acquired a new position in Agenus in the fourth quarter worth $130,000. Cubist Systematic Strategies LLC acquired a new position in Agenus in the third quarter worth $134,000. OxFORD Asset Management LLP acquired a new position in Agenus in the second quarter worth $141,000. Finally, Voya Investment Management LLC boosted its holdings in Agenus by 18.5% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 6,381 shares during the period. 37.35% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2018/02/18/bidaskclub-upgrades-agenus-agen-to-hold.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.